BRCA1 and Familial prostate cancer: Pathogenic mutations in BRCA1 and BRCA2 genes are thus predictive biomarkers for PARPi sensitivity in breast, ovarian, pancreatic, and prostate cancers, and are approved as companion test for PARPi indications [3].